(PUB) Investing 2016

7

January 2016

Morningstar FundInvestor

Data through December 31, 2015 FINRA members: For internal or institutional use only. T. Rowe Price Blue Chip Growth

Ticker TRBCX

Yield 0.0%

Total Assets $31,007 mil

Mstar Category Large Growth

Benchmark 1: Russell 1000 Growth TR USD Benchmark 2: S&P 500 TR USD Morningstar Analyst Rating 12-11-15 „

Investment Style Equity

Historical Profile Return Risk Rating High Above Avg QQQQQ Highest

7 7 7 7 7 7 7 7

20.0 25.0

Growth of $10,000

Investment Values of Fund Investment Values of Benchmark 1

15.0

Morningstar Pillars Process

∞ Positive ∞ Positive ∞ Positive ∞ Positive ∞ Positive

10.0

Performance

People Parent

Performance Quartile (within Category)

( & * ( & * & & & ( & 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 12-15 32.68 35.73 40.23 23.01 32.77 38.13 38.65 45.63 64.60 67.27 72.38 5.95 9.73 13.02 -42.62 42.57 16.42 1.50 18.41 41.57 9.28 11.15 0.68 0.65 1.21 -4.19 5.36 -0.29 -1.14 3.16 8.09 -3.77 5.48 1.03 -6.07 7.53 -5.63 16.10 1.35 -0.61 2.41 9.19 -4.41 9.76 0.26 0.40 0.42 0.17 0.15 0.06 0.13 0.35 0.00 0.00 0.00 5.69 9.33 12.60 -42.80 42.42 16.36 1.37 18.07 41.57 9.27 11.15 0.08 0.13 0.15 0.07 0.04 0.02 0.05 0.14 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.26 2.36 0.85 0.81 0.77 0.80 0.81 0.77 0.77 0.76 0.74 0.72 0.70 0.28 0.36 0.42 0.22 0.15 0.08 0.12 0.32 0.03 -0.02 0.03 53 25 48 69 20 39 17 18 7 60 3

Price

History

Morningstar Analyst Rating Morningstar evaluates mutual funds based on five key pillars, which its analysts believe lead to funds that are more likely to outperform over the long term on a risk-adjusted basis. Analyst Rating Spectrum Œ „ ´ ‰ Á

NAV

Total Return % +/- Bmark 1 +/- Bmark 2 Income Return % Capital Return % Capital Gains $ Expense Ratio % Income Ratio % Turnover Rate % Net Assets $mil Total Rtn % Rank Cat Income $

Pillar Spectrum ∞ Positive

§ Negative

¶ Neutral

Performance 12-31-15 1st Qtr 2nd Qtr

3rd Qtr

4th Qtr

Total

2011 2012 2013 2014 2015

5.74 0.72 -13.52 10.20 1.50 18.76 -5.45 6.34 -0.83 18.41 8.15 3.69 11.94 12.78 41.57 -1.10 4.16 1.73 4.27 9.28 5.96 0.49 -4.98 9.86 11.15

. .

44

39

32

54

60

47

44

25

35

33

7,998 8,811 11,296 6,727 9,461 10,970 10,597 13,692 20,230 23,276

Rating and Risk Time Period Load-Adj Return %

Portfolio Analysis 09-30-15 Total Stocks: 125 Share change since 06-30-15

Morningstar Rtn vs Cat

Morningstar Risk vs Cat

Morningstar Risk-Adj Rating

Sector

YTD Ret % % Assets

Trailing

Total Return%

+/- Bmark 1

+/- Bmark 2

%Rank Cat

Growth of $10,000

T Amazon.com Inc

Cnsmr Cyc 117.78 6.30

1 Yr 3 Yr 5 Yr

11.15 19.80 15.63

3 Mo 6 Mo

9.86 2.54 2.82 4.38 2.74 4.23 11.15 5.48 9.76 19.80 2.97 4.68 15.63 2.10 3.06 9.33 0.80 2.03 5.94 1.61 4.33

3 10,986 5 10,438 3 11,115 3 17,195 1 20,666 8 24,408 14 23,770

T Alphabet Inc Class C Capi T Priceline Group Inc T Facebook Inc Class A

Technology Cnsmr Cyc Technology Finan Svcs Finan Svcs Technology Industrl

— 3.77

+Avg QQQQQ +Avg QQQQQ +Avg QQQQQ

High High High

11.82 3.49 34.15 3.29 9.00 3.14 19.07 2.91 13.74 2.71 46.60 2.44 — 2.33 -4.49 2.31 3.09 2.20 7.06 2.05 22.22 2.01 8.72 1.92 -2.80 1.78 47.98 1.74 32.19 1.58 -0.09 1.55 18.23 1.54 38.06 1.29 1.47 0.48 26.02 1.36 10.57 2.02 0.00 0.00 33.62 0.80 3.17 0.62 0.54 1.02 10.66 0.86 19.25 0.81 28.32 0.99 1.96 0.18 26.36 1.48 0.00 0.00 — 1.77 % of Stocks Rel Bmark 1

1 Yr

10 Yr Incept

9.33

3 Yr Avg 5 Yr Avg 10 Yr Avg 15 Yr Avg

T Danaher Corp T Visa Inc Class A

10.41

T MasterCard Inc Class A Y Alphabet Inc Class A

Other Measures

Standard Index

Best Fit Index

Alpha

3.8

1.6

T Allergan PLC Y McKesson Corp

Hlth Care Hlth Care Hlth Care Hlth Care

Beta

1.02

1.02

Tax Analysis

Tax Adj Rtn% %Rank Cat Tax-Cost Rat %Rank Cat

R-Squared

79

92

3 Yr (estimated) 5 Yr (estimated) 10 Yr (estimated)

19.05 15.15

1 1 4

0.63 0.41 0.25

14 13

T Alexion Pharmaceuticals I

Standard Deviation

12.29 19.80

T Celgene Corp T Microsoft Corp

9.06

9

Mean

Technology

Sharpe Ratio

1.54

Y Gilead Sciences Inc

Hlth Care

Potential Capital Gain Exposure: 41% of assets

Y Apple Inc

Technology Hlth Care Cnsmr Cyc Technology Comm Svcs

Morningstar's Take by Katie Rushkewicz Reichart, CFA 12-11-15 T. Rowe Price Blue Chip Growth has excelled during manager Larry Puglia's 22-year tenure, supporting its Morningstar Analyst Rating of Silver.

T Valeant Pharmaceuticals I Y Starbucks Corp T Salesforce.com Inc Y American Tower Corp T UnitedHealth Group Inc

pricing of its drugs, the fund has had a stellar year in 2015 as other stocks in its diversified portfolio produced big gains. In particular, longtime holding and top position Amazon.com AMZN had a banner year, and the position grew to over 6% of assets by September. It also got a boost from Netflix NFLX, Alphabet GOOGL, and Facebook FB. The fund occasionally stumbles in market pullbacks, and it's lostabitmore than theRussell1000Growth Index in down markets during the past decade. Certain positioning, such as its above-average biotech stake relative to the benchmark, could weigh on results if there's an industrywide sell-off. Longer term, there's also the question of capacity across T. Rowe's large-growth funds (this strategy alone is $50 billion in assets). However, on the whole the fund has done a good job of producing strong risk-adjusted results during Puglia's tenure.Reasonablecostsalsohelp thecase for this fund's Silver rating.

Hlth Care

Beyondbenefiting fromanexperiencedmanager, the fund draws on T. Rowe's analyst team for stock ideas, which has proved quite capable at finding successful large-growth names. The fund has consistently produced strong returns relative to its large-growth Morningstar Category peers and the Russell 1000 Growth Index, even in recent years when it's been difficult for many active- equity managers to beat passive index funds. Puglia looks forcompanieswithsustainableearnings, free cash flow growth, and management teams that will drive further growth. While the fund's active share (its differentiation from the benchmark) isn't exceptionally high, the fund makes enough bets to meaningfully distinguish itself fromaperformancestandpoint. In recent years, that's included a significant stake in healthcare stocks, which has boosted results. Despite owning a top-20 position in Valeant Pharmaceuticals VRX as of September 2015, which subsequently stumbled upon concerns about aggressive

Current Investment Style

Sector Weightings h Cyclical r BasicMat t CnsmrCyc y FinanSvcs u Real Est j Sensitive i CommSrvs o Energy p Industrl a Technlgy k Defensive s CnsmrDef d Hlthcare f Utilities

Market Cap % Giant 46.1 Large 46.5 Mid 7.4 Small 0.0 Micro 0.0 Avg $mil: 64,145

Value Blend Growth

Large Mid Small

Value Measures

Rel Category

Price/Earnings 22.88

1.02 1.06 0.82 1.09 0.64 1.17 1.39 1.12 0.98 1.29

Price/Book Price/Sales

4.09 1.91

Price/Cash Flow 14.94 Dividend Yield % 0.80

Growth Measures

% Rel Category

Long-Term Erngs 15.26

Book Value

13.14

Composition - Net

Sales

9.73

Cash 0.3 Stocks 99.7 Bonds 0.0 Other 0.0 Foreign 7.9 (% of Stock)

Address:

T. Rowe Price Blue Chip Growth Fund, Inc

Minimum Purchase: Min Auto Inv Plan:

$2500 $2500

Add: $100 IRA: $1000

Cash Flow 11.50 Historical Erngs 16.05

Baltimore MD 21202

Add: $100

800-638-5660

Sales Fees:

No-load

Web Address:

www.troweprice.com

Management Fee:

0.30% mx./0.26% mn., 0.15%A

Profitability

%

Inception:

06-30-93

Actual Fees:

Mgt:0.57% Dist:0.00%

Return on Equity Return on Assets

19.85

Advisor:

T. Rowe Price Associates, Inc.

Expense Projections: Income Distribution:

3Yr:$230 5Yr:$401 10Yr:$894

8.72

Subadvisor:

None

Annually

Net Margin

13.95

A

ß ® Mutual Funds

©2016Morningstar, Inc.All rights reserved. The information herein is not represented orwarranted to be accurate, complete or timely. Past performance is no guarantee of future results.Access updated reports at www.morningstar.com . To order reprints, call 312-696-6100.